XML 67 R54.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration and Licensing Agreements (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Oct. 31, 2017 USD ($) shares | Mar. 31, 2017 USD ($) | Jul. 31, 2016 USD ($) | Jun. 30, 2016 USD ($) item | Sep. 30, 2015 USD ($) item | Dec. 31, 2014 USD ($) | Jul. 31, 2013 USD ($) item | Jan. 31, 2013 USD ($) item | Jun. 30, 2010 USD ($) | Feb. 28, 2009 item | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) item | Dec. 31, 2016 USD ($) | Dec. 31, 2007 item
License Agreement | Merck Sharp & Dohme Corp. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 | $ 0 |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  | 0 |  |  |
Annual maintenance fees |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |
Number of compounds | item |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |
License Agreement | INmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fully-diluted equity interests (as a percentage) | 19.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional equity interests (as a percentage) | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issued in shares | shares | 1,585,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity issues, value | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 100,000 |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |  |
Option and license agreement | Alexion Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  | 11,000,000 | $ 9,000,000 |  | 20,000,000 | 0 | 5,000,000 |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |  |
Number of different target programs | item |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |
Research license term |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |
Annual maintenance fees |  |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  |  |  |  |  |  |  |  |  |  |  | 36,500,000 |  |  |
2009 Research License and Commercialization Agreement | CSL Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  | $ 3,500,000 |  |  |  |  |  |  |  |  |  |  |  | 0 | 3,500,000 | 0 |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |  |
Collaboration And License Agreement | Novartis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  | $ 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000 | 20,100,000 | 69,900,000 |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 40,100,000 |  | $ 60,100,000 | 40,100,000 | 60,100,000 |  |
Contract receivable |  |  |  |  |  |  |  |  |  |  | 2,100,000 |  |  | 2,100,000 |  |  |
Collaboration And License Agreement | Novartis | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  |  | 2,100,000,000 |  |  | $ 2,100,000,000 |  |  |
Collaboration And License Agreement | Novartis | Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Right to substitute identified target period |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |
Collaboration And License Agreement | Novartis | Bispecific FC Technologies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of development stage products | item |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of previously identified products | item |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |
Research license term |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb14045 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocation of consideration to deliverables |  |  |  | $ 27,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb13676 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocation of consideration to deliverables |  |  |  | $ 31,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of antibody targets for which bispecific technology applied | item |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Global Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of programs where Company has the right to participate | item |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  | $ 20,040,000 |  |  | 20,050,000 |  |
Percentage of responsibility for development costs |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of responsibility for commercialization costs |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of profits on net sales of the product |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Allocation of consideration to deliverables |  |  |  | $ 20,050,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of discovery programs | item |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Global Discovery Program | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of antibody targets for which bispecific technology applied | item |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | FC Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocation of consideration to deliverables |  |  |  | $ 11,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | FC Licenses | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of targets against which non-exclusive license is provided | item |  |  |  | 10 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novo Nordisk A/S |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  | $ 2,500,000 |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 | 0 | 2,700,000 |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |  |
Research license term |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |
Milestone payment received |  |  |  |  |  | $ 1,600,000 |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | MorphoSys |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  |  | $ 13,000,000 |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 12,500,000 | 0 |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |  |
Research and License Agreement 2015 | Amgen, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  | $ 45,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  | $ 600,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 600,000 | 10,000,000 | 31,200,000 |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |  |
Allocation of consideration to deliverables |  |  |  |  |  |  |  |  |  |  | 55,500,000 |  |  | 55,500,000 |  |  |
Research and License Agreement 2015 | Amgen, Inc. | ASU 2014-09 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 31,250,000 |
Research and License Agreement 2015 | Amgen, Inc. | CD38 Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |
Allocation of consideration to deliverables |  |  |  |  |  |  |  |  |  |  | 23,750,000 |  |  | 23,750,000 |  |  |
Research and License Agreement 2015 | Amgen, Inc. | Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  | 500,000 |  |  |  |  |  |
Research license term |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |
Allocation of consideration to deliverables |  |  |  |  |  |  |  |  |  |  | 6,250,000 |  |  | 6,250,000 |  |  |
Number of discovery programs | item |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |
Additional research term |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |
Previous targets which bispecific technology will be applied | item |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |
Number of delivered discover programs | item |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |
Research Licensee and Collaboration Agreement 2007 Agreement | CSL Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of commercial licenses | item |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |
Research Licensee and Collaboration Agreement 2007 Agreement | Boehringer Ingelheim International GmbH |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | $ 0 | $ 0 |
Deferred revenue |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  | $ 0 |  |  |
Research license term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years
Number of commercial options | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1
Number of compounds | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |
Number of commercial licenses | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |

X
- Definition Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of antibody targets for which bispecific technology applied. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementBispecificTechnologyAppliedNumberOfAntibodyTargets
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of FC technology targets for which non-exclusive license is provided. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementNonExclusiveLicenseProvidedNumberOfFcTechnologiesTargets
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of programs under the collaborative agreements. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementNumberOfPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of profit on net sales of the product, if the company elects to participate in development. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementPercentageOfProfitOnNetSales
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of responsibility assumed for commercialization costs, if the company elects to participate in development. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementPercentageOfResponsibilityAssumedForCommercializationCosts
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of responsibility assumed for development costs, if the company elects to participate in development. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementPercentageOfResponsibilityAssumedForDevelopmentCosts
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the additional period for which research term may be extended under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementAdditionalResearchTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of nonrefundable upfront fees as provided under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementAnnualMaintenanceFees
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payment received under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementMilestonePayment
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of nonrefundable upfront fees as provided under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNonrefundableUpfrontFees
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of commercial options provided under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfCommercialOptions
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of compounds. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfCompounds
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of different target programs under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfTargetPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the research license term under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementResearchLicenseTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of commercial licenses exercised in association with a research agreement. + References No definition available. + Details
Name: | xncr_NumberOfCommercialLicenses
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of discover programs delivered. + References No definition available. + Details
Name: | xncr_NumberOfDeliveredDiscoverPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of development stage products that incorporate the company's bispecific Fc technology. + References No definition available. + Details
Name: | xncr_NumberOfDevelopmentStageProducts
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents information pertaining to the previously identified programs that can be substituted during the research term provided Amgen has not initiated non human primate studies + References No definition available. + Details
Name: | xncr_NumberOfPreviousIdentifiedProductsInWhichSubstitutionCanOccur
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of programs which the Company has the right to participate in the development and commercialization. + References No definition available. + Details
Name: | xncr_NumberOfProgramsRightToParticipate
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of additional equity interests available to be obtained in a license agreement. + References No definition available. + Details
Name: | xncr_PercentageOfAdditionalEquityInterests
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of fully-diluted equity interest in a collaboration agreement. + References No definition available. + Details
Name: | xncr_PercentageOfFullyDilutedEquityInterest
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents information in which bispecific technology will be applied to previous targets + References No definition available. + Details
Name: | xncr_PreviousTargetsWhichBispecificTechnologyWillBeApplied
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. + References No definition available. + Details
Name: | xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of years the company has the right to substitute an identified target from the effective date of the Agreement. + References No definition available. + Details
Name: | xncr_RightToSubstituteIdentifiedTargetPeriod
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_MerckSharpAndDohmeCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_InmuneBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_OptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseAndCommercialization2009AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_CSLLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_DiscoveryProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_BispecificFcTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_Xmab14045ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_Xmab13676ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_GlobalDiscoveryProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_FcLicensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_NovoNordiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchAndLicenseAgreement2015Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_Cd38ProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseeAndCollaborationAgreement2007AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_BoehringerIngelheimInternationalGmbhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |